Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error. Digital ...

Akili Interactive hit the public markets in August, bringing in cash the company will use to launch its video game digital therapeutic for children with ADHD later this year. Akili's product, dubbed ...

Following its recent $30 million fundraise to advance its video game platform for neurological conditions such as attention deficit hyperactivity disorder and Alzheimer’s disease, Akili Interactive ...

Akili Interactive (“Akili” or the “Company”), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become ...

Following positive top-line data released in May, Akili Interactive announced it will release its video game treatment for attention deficit hyperactivity disorder to adults who want to use it.

In a far cry from the old adage that too much screen time will rot the brain, Akili Interactive is developing video games clinically proven to improve cognitive function—backed by an FDA green light ...

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal ...

After nearly a decade of work, Akili Interactive received the green light from the FDA to market its video game as a treatment for ADHD. It wasn’t an easy feat, and the company still has a long road ...

Akili Interactive, a company that treats attention-deficit disorders with its video games, will go public by merging with a blank-check firm led by serial dealmaker Chamath Palihapitiya in a deal ...

Less than two years after scoring its first FDA clearance, Akili Interactive is betting big on its digital therapeutic technology. The Massachusetts-based company has signed a reverse-merger deal with ...

Akili Interactive ("Akili" or "Company"), a leading prescription digital medicine company developing novel treatments for cognitive dysfunction, today announced that it has successfully closed a $55 ...